Barely Significant
← all excerpts

Real-time continuous glucose monitoring-guided glucose management in inpatients with diabetes receiving short-term continuous subcutaneous insulin infusion: a randomized clinical trial.

Lancet Reg Health West Pac · 2024 · PMC11305887 · PMID 39119238

Europe PMCDOI
1
hedged sentence
0.0400
closest p · 0.8× alpha
0.0400
boldest claim

The sentences

borderline significantP = 0.04actually significant
Other outcomes and adverse events The total daily insulin dose was 0.49 ± 0.12 units/kg/day in the rtCGM group and 0.51 ± 0.13 units/kg/day in the POC group, with a borderline significant difference (P = 0.04).

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.